Caitong International Asset Management Co. Ltd Has $150,000 Holdings in AstraZeneca PLC $AZN

Caitong International Asset Management Co. Ltd raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 322.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,149 shares of the company’s stock after acquiring an additional 1,640 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in AstraZeneca were worth $150,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Lindbrook Capital LLC grew its stake in AstraZeneca by 1.9% in the first quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock valued at $557,000 after acquiring an additional 141 shares during the period. Principal Securities Inc. grew its stake in AstraZeneca by 0.5% in the first quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock valued at $2,062,000 after acquiring an additional 142 shares during the period. Sage Mountain Advisors LLC grew its stake in AstraZeneca by 3.4% in the first quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock valued at $329,000 after acquiring an additional 147 shares during the period. Richardson Financial Services Inc. grew its stake in AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares during the period. Finally, Evergreen Capital Management LLC grew its stake in AstraZeneca by 0.7% in the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock valued at $1,743,000 after acquiring an additional 155 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Price Performance

NASDAQ:AZN opened at $83.40 on Friday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average price is $80.79 and its two-hundred day moving average price is $74.22. The firm has a market capitalization of $258.66 billion, a price-to-earnings ratio of 31.35, a P/E/G ratio of 1.54 and a beta of 0.36. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $86.57.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.24 earnings per share. On average, analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s dividend payout ratio is presently 37.97%.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of research analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Finally, Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.